FDA Issues Draft Guidance on Cannabis Clinical Research and Sends CBD Enforcement Discretion Guidance to OMB for Review

Published date29 July 2020
Subject MatterMarijuana,FDA,Farm Bill,Clinical Trials,OMB,Controlled Substances Act,DEA,Draft Guidance,Investigational New Drug Application (IND),Cannabidiol (CBD) oil,Cannabis Products
AuthorJames Boiani,Megan Robertson,Delia Deschaine
Law FirmEpstein Becker & Green

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT